Covance Drug Development (a LabCorp company) has relocated its clinical research unit (CRU) in Dallas, TX, to a new, 55,000 sq.-ft., fit-for-purpose clinical research facility. The newly opened unit has expanded from 72 to 100 beds and is located in the same building as the prior unit. Also, a LabCorp patient service center will be co-located in the CRU, where patients will have an opportunity to learn more about volunteering and participating in early stage trials.

The CRU includes a cGMP pharmacy, ophthalmology procedure rooms, an advanced telemetry system, and a glucose clamp suite, as well as dedicated screening and outpatient visit areas. The pharmacy includes three sterile and two non-sterile GMP manufacturing suites.

“Our new Dallas facility combines advanced medical care with numerous volunteer-friendly amenities,” said Dr. Herman Scholtz, vice president and general manager, Early Clinical Services. “We have invested in a highly customized facility designed to facilitate the safety and quality of our studies and to enhance our clients’ and volunteers’ experience. In addition, we are excited about the unique opportunity to educate patients about our clinical trials and complement our local patient recruitment capabilities through the future LabCorp patient service center. This innovative combination of resources is another illustration of the strategic and operational synergies that LabCorp and Covance are gaining through our combination.”